Literature DB >> 22301494

Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy.

Hector H Li Chang1, W Robert Leeper, Gabriel Chan, Douglas Quan, David Kevin Driman.   

Abstract

The response of colorectal adenocarcinoma liver metastases to perioperative chemotherapy can be assessed histologically in partial hepatectomy specimens. Necrosis in this scenario may represent a lack of treatment effect or a therapeutic response to chemotherapy. This study sought to validate the histologic classification of necrosis into 2 types: usual necrosis (UN) representing an absence of treatment effect, and infarct-like necrosis (ILN) representing a therapeutic response to chemotherapy. Tumor regression grade (TRG) is a previously described prognosticating method that estimates tumor replacement by fibrosis. We incorporated ILN into a modified TRG (mTRG) and compared its performance as a prognostic factor against TRG. A retrospective clinical and histologic review was undertaken of all partial hepatectomies performed for colorectal liver metastases at our center between 2004 and 2010. Clinicopathologic features were compared between the 2 types of necrosis, including survival stratified by TRG and mTRG. A total of 109 cases were reviewed, with 46 patients receiving perioperative chemotherapy. ILN was identified in 12 cases, and all of these cases were associated with perioperative chemotherapy. ILN was significantly associated with perioperative treatment with bevacizumab. In patients receiving perioperative chemotherapy, those with ILN had superior disease-free survival compared with those with UN (P=0.047). mTRG1 to 2 scores were associated with significantly better survival compared with mTRG3 to 5 scores. In contrast, use of TRG did not demonstrate a significant difference in disease-free and overall survival. ILN represents a form of treatment effect and should be distinguished from UN. A modified grading system that incorporates ILN may enhance the prognostic utility of TRG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301494     DOI: 10.1097/PAS.0b013e31824057e7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Safety analysis of the oncological outcome after vein-preserving surgery for colorectal liver metastases detached from the main hepatic veins.

Authors:  Federico Tomassini; Italo Bonadio; Peter Smeets; Karen De Paepe; Giammauro Berardi; Liesbeth Ferdinande; Stéphanie Laurent; Louis J Libbrecht; Karen Geboes; Roberto I Troisi
Journal:  Langenbecks Arch Surg       Date:  2015-08-12       Impact factor: 3.445

3.  Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy.

Authors:  M L Gómez Dorronsoro; R Vera; L Ortega; C Plaza; R Miquel; M García; E Díaz; M R Ortiz; J Pérez; C Hörndler; C Villar; J Antúnez; S Pereira; F López-Rios; R González-Cámpora
Journal:  Clin Transl Oncol       Date:  2013-09-10       Impact factor: 3.405

4.  Radiological Morphology of Colorectal Liver Metastases after Preoperative Chemotherapy Predicts Tumor Viability and Postoperative Outcomes.

Authors:  Yujiro Nishioka; Junichi Shindoh; Ryuji Yoshioka; Wataru Gonoi; Hiroyuki Abe; Naoki Okura; Shuntaro Yoshida; Masaru Oba; Masaji Hashimoto; Goro Watanabe; Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

5.  Extended pathology reporting of resection specimens of colorectal liver metastases: the significance of a tumour pseudocapsule.

Authors:  Matthew G Wiggans; Golnaz Shahtahmassebi; Paul Malcolm; Frances McCormick; Somaiah Aroori; Matthew J Bowles; David A Stell
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

6.  Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.

Authors:  K Dede; T Mersich; I Besznyák; A Zaránd; F Salamon; Z S Baranyai; L Landherr; F Jakab; A Bursics
Journal:  Pathol Oncol Res       Date:  2013-02-19       Impact factor: 3.201

7.  Clinical and Radiologic Predictors of a Pathologic Complete Response to Neoadjuvant Chemotherapy (NACT) in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: Results of a Prospective Multi-center Study.

Authors:  Aditi Bhatt; Pascal Rousset; Nazim Benzerdjeb; Praveen Kammar; Sanket Mehta; Loma Parikh; Gaurav Goswami; Sakina Shaikh; Vahan Kepenekian; Guillaume Passot; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2020-11-18       Impact factor: 5.344

8.  Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer.

Authors:  Ayako Tomono; Kimihiro Yamashita; Kiyonori Kanemitsu; Yasuo Sumi; Masashi Yamamoto; Shingo Kanaji; Tatsuya Imanishi; Tetsu Nakamura; Satoshi Suzuki; Kenichi Tanaka; Yoshihiro Kakeji
Journal:  Int J Clin Oncol       Date:  2015-09-04       Impact factor: 3.402

9.  Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use?

Authors:  K Dede; F Salamon; L Landherr; F Jakab; A Bursics
Journal:  Pathol Oncol Res       Date:  2014-06-05       Impact factor: 3.201

Review 10.  Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.

Authors:  Aditi Bhatt; Suniti Mishra; Loma Parikh; Sandeep Sheth; Imran Gorur
Journal:  Indian J Surg Oncol       Date:  2019-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.